Tyrosinase Inhibitors With Enhanced Potency in Mammalian and Vertebrate Models, N ‐(2‐Mercaptoethyl)benzamide Derivatives: Design, Synthesis, and Evaluation
Chemical Biology & Drug Design · 2026
DOI: 10.1111/cbdd.70383 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2026. Verfasst von Hyunhee Ju und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Republic of …. Hauptthemen laut MEDLINE: Monophenol Monooxygenase, Benzamides, Enzyme Inhibitors, Drug Design. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pusan National University.
Abstract (Originalsprache)
Retaining structural features that allow 2‐mercaptomethylbenzimidazole compounds to function as Cu(II) chelators, N ‐(2‐mercaptoethyl)benzamide (NMEB) derivatives 1a – 1m were designed, synthesized, and assessed for their potential as Cu(II) chelators. Derivative 1m inhibited mushroom tyrosinase (mTYR) activity twice as potently as kojic acid (KA) in the presence of l ‐DOPA. The mechanisms by which three derivatives, including 1m , inhibit mTYR were elucidated through kinetic studies. Interestingly, all NMEB derivatives suppressed melanogenesis more potently than KA in B16F10 cells, significantly reducing melanin production in a concentration‐dependent manner. NMEB derivatives also inhibited cellular TYR activity in keeping with their melanogenesis inhibition, indicating B16F10 cellular TYR inhibition to be the primary mechanism. Moreover, among these derivatives, 1a inhibited zebrafish larval pigmentation hundreds of times more potently than KA. In mammalian cells and zebrafish larvae, NMEB derivatives showed even higher TYR‐inhibitory or antimelanogenesis potency than mushrooms. Due to differences in the amino acid sequence and location of TYRs, NMEB derivatives appear to differ in their inhibition of TYR activity and melanin production in different species. This study points out limitations in the development of novel TYR inhibitors based on mTYR inhibition results and provides fundamental data supporting their development as novel skin‐lightening agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Manufacturing Pharmacy, College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.
- Department of Pharmacy, College of Pharmacy, Pusan National University, Busan, Republic of Korea.
ORCID-Profile: Hyunhee Ju, Minchang Kim, Hee Jin Jung, Yeonsoo Jeong, Hae Young Chung, Hyung Ryong Moon
Förderung
- Pusan National University
Zitieren
APA
Ju, H., Kim, M., Lee, H., Jung, H. J., Jeong, Y., Kang, H., Park, H. S., Chung, H. Y., & Moon, H. R. (2026). Tyrosinase Inhibitors With Enhanced Potency in Mammalian and Vertebrate Models, N ‐(2‐Mercaptoethyl)benzamide Derivatives: Design, Synthesis, and Evaluation. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70383
Vancouver
Ju H, Kim M, Lee H, Jung HJ, Jeong Y, Kang H, et al. Tyrosinase Inhibitors With Enhanced Potency in Mammalian and Vertebrate Models, N ‐(2‐Mercaptoethyl)benzamide Derivatives: Design, Synthesis, and Evaluation. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70383
BibTeX
@article{Ju2026,
author = {Ju, Hyunhee and Kim, Minchang and Lee, Hyunju and Jung, Hee Jin and Jeong, Yeonsoo and Kang, Hyejin and Park, Hyeon Seo and Chung, Hae Young and Moon, Hyung Ryong},
title = {Tyrosinase Inhibitors With Enhanced Potency in Mammalian and Vertebrate Models, N ‐(2‐Mercaptoethyl)benzamide Derivatives: Design, Synthesis, and Evaluation},
journal = {Chemical Biology & Drug Design},
year = {2026},
doi = {10.1111/cbdd.70383}
}
EUVIMED